Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2/3 study of KPG-121 in combination with Abiraterone as a first-line treatment of metastatic castration resistant prostate cancer (mCRPC)

Next Previous
Trial Profile

Phase 2/3 study of KPG-121 in combination with Abiraterone as a first-line treatment of metastatic castration resistant prostate cancer (mCRPC)

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 11 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone (Primary) ; KPG-121 (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use

Most Recent Events

  • 11 Jun 2024 New trial record
  • 05 Jun 2024 According to Kangpu Biopharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has recently approved a Phase II/III clinical trial of KPG-121 in combination with Abiraterone for a first-line treatment of metastatic castration resistant prostate cancer (mCRPC).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top